Lpathomab

Drug Profile

Lpathomab

Alternative Names: Anti-LPA MAbs - Lpath; Lpathomab; mAb against lysophosphatidic acid (LPA) - Lpath

Latest Information Update: 23 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lpath
  • Developer Lpath; University of California at Los Angeles; University of Melbourne
  • Class Monoclonal antibodies
  • Mechanism of Action Lysophosphatidic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Brain injuries; Fibrosis; Spinal cord injuries
  • Research Diabetic neuropathies
  • No development reported Cancer

Most Recent Events

  • 20 Jun 2016 Lpath receives grant from the US Department of Defense for the preclinical development of Lpathomab™ in Neuropathic pain
  • 19 Apr 2016 Pharmacokinetics and adverse event data from phase I trial in Neuropathic pain (In volunteers) released by Lpath
  • 19 Apr 2016 Lpath completes a phase I trial in Neuropathic pain (In volunteers) in USA (Parenteral) (NCT02341508)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top